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Abstract 
Background: There are many different methodologies used in the literature for determining the number of drugs 
used by a patient, and many are incompletely described. This may be attributable to the lack of a framework to help 
investigators choose and describe their methods and the lack of evidence on the implications of the choice. The pur-
pose of the study was to propose a framework and illustrate how that framework can be used to create and succinctly 
describe various approaches to counting the number of drugs used by patients and to examine the impact of varying 
individual components of the framework on the resulting drug count.
Methods: The three component framework requires specification of scope, uniqueness, and timeframe. The frame-
work was applied to Medicare beneficiaries admitted for acute myocardial infarction in 2008. Drug use was ascer-
tained by Part D prescription drug event files. A default measure for drug count was established, and fourteen addi-
tional measures were created by separately altering individual components of the default to illustrate the application 
of the framework and understand how these changes impacted drug count. Median drug counts and the frequency 
distributions of beneficiaries experiencing a change in count from default were produced for each measure.
Results: The median drug count for the default measure was 4. Alteration of the timeframe component had the 
largest impact on drug counts, with a look-back period of 180 days producing a median count of 8 and changing the 
count by at least two for 73 % of patients. Variations of the other components had less impact.
Conclusion: Our framework is intended to be used by investigators to select an approach to counting number of 
drugs in their studies. Extending the timeframe over which fills from a pharmacy refill database could be counted 
toward the drug count produced the greatest changes in the number of drugs.
Keywords: Drug count, Framework, Pharmacy refill database, Medicare, Acute myocardial infarction
© 2016 Goedken et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Determining the number of drugs used by a patient is 
necessary for a variety of research applications. For exam-
ple, an investigator’s objective may be to assess trends in 
drug use within a population [1] or seek predictors of the 
number of drugs used [2]. Number of drugs may serve 
as an indicator of comorbidity [3] or regimen complex-
ity [4] and be included as a covariate. Regardless of pur-
pose, an investigator must select a method for measuring 
number of drugs and is confronted with a plethora of 
approaches that have been used in the existing literature. 
Often these approaches are incompletely described, if at 
all, and therefore difficult to replicate. One possible con-
tributor to the abundance of methodologies and lack of 
adequate description is the absence of a framework to 
assist investigators in selecting and succinctly describing 
their methods.
Another possible contributor to the variety of 
approaches used is the lack of studies demonstrating 
the impact of the chosen methodology on patient drug 
counts. The few available studies have provided descrip-
tive statistics regarding the distribution of number of 
drugs under selected methods [5–7] but have not char-
acterized how drug counts are sensitive to altering spe-
cific components of a measure. Differences in counts 
between two studies using non-uniform methods can 
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lead to misleading inferences. For example, the effect of 
drug counts on adherence to a newly prescribed drug 
may vary across two studies. These inconsistent results 
may simply be caused by different methods to count 
drugs across studies. Evidence on how many patients’ 
counts change and how much their counts change with 
particular changes in methodology is needed to aid in the 
evaluation of the robustness of published study findings 
examining number of drugs.
Therefore, the first objective of this study was to pro-
pose a framework and illustrate how that framework 
can be used to create and succinctly describe various 
approaches to counting the number of drugs used by 
patients. The second objective was to examine the impact 
of varying individual components of the framework on 
the resulting drug count, using a pharmacy refill database 
as the source of drug regimen information, and applied 
to a cohort of Medicare patients with Part D benefits that 




We propose a three component framework to be consid-
ered when creating and describing methods for counting 
the number of drugs used by a patient (Table 1). Impor-
tantly, we do not advocate the creation of a single stand-
ard measure, as it should be allowed to vary according to 
study specific objectives. This framework applies regard-
less of the purpose for measuring number of drugs and 
requires the specification of three components. The first 
component is scope, which refers to the types of prod-
ucts that will be included or excluded as being drugs. 
Examples of products that could be excluded are over-
the-counter drugs or drugs with specific routes of admin-
istration. The second component is uniqueness, which 
describes how drugs should be counted where combina-
tion products with multiple active ingredients are con-
cerned and in the case where a single ingredient may 
be found in multiple products in a regimen. The basic 
approaches are to count unique ingredients or unique 
products. The final component is timeframe, which 
requires specification of a cross-sectional versus longitu-
dinal orientation. Each component requires the investi-
gator to establish a conceptual definition and then select 
operational criteria that best approximate the conceptual 
definition as allowed by the available data. As an exam-
ple related to the timeframe component, a commonly 
used operational criterion is the number of drugs dis-
pensed in the 6 months or year prior to an index event. 
The intended conceptual definition may be a longitudinal 
orientation.
Patients and data source
Patients examined in this analysis were drawn from a 
study comparing the effectiveness of AMI combination 
treatments on survival, side effects, and costs [8]. Medi-
care enrollment and medical claim files from the Chronic 
Condition Data Warehouse data were used to select 
patients. Beneficiaries were required to be admitted and 
discharged for an AMI in 2008, with no history of AMI 
in the prior 12 months. Their index date was the date of 
admission. They were also required to survive for at least 
30 days following discharge from their index hospitaliza-
tion and not have any inpatient, skilled nursing facility 
claim, or hospice claims during this period. All benefi-
ciaries had continuous fee-for-service Medicare Part 
A, B, and D coverage in the 12 months before the index 
hospitalization and until death or 12  months after hos-
pitalization, whichever came first. Additional selection 
criteria included residence in the lower 48 US states and 
age ≥66 years old at index date.
Drug use data
Drug use by AMI patients during 2007 through 2009 
for drug counts was ascertained by Part D prescription 
drug event (PDE) files from the Chronic Condition Data 
Warehouse. Specific product information (e.g. ingredi-
ents, route, dosage form, etc.) was identified by linking 
these files to a commercially available drug information 
resource (Multum Lexicon) using National Drug Codes 
(NDC) (http://www.multum.com/lexicon.html). PDEs 
for medical supplies were excluded. PDEs that could not 
be matched or contained days supplied values of 0 or 999 
were excluded as needed to apply the various criteria for 
determining drug count, resulting in a loss of less than 
0.05 % of PDEs.
Variant measures for drug count
A default measure for drug count was first established in 
order to examine the impact of varying individual com-
ponents of the three component framework. For the 
default, scope was limited to prescription drug prod-
ucts, uniqueness was determined using a product-based 
approach, and timeframe was cross-sectional (Table  2). 
Additional measures were created by separately altering 
individual components to understand how these changes 
impacted drug count, leaving the remaining two compo-
nents unaltered and as specified for the default. A total 
of 14 variations were created, for illustration, and should 
not be perceived as all possible variations that could be 
appropriate for particular research applications (Table 2). 
Counts under each of the 15 measures were generated 
for each AMI patient. To illustrate the application of 
each drug count measure, drug counts for a hypothetical 
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patient (Table 2) were calculated from a hypothetical fill 
history (Table  3). Variants 1–4 are alterations of scope. 
Variant 1 altered the values allowed under the prescrip-
tion drug status subcomponent. Variants 2 and 3 altered 
the values allowed under the route of administration 
subcomponent. Variant 4 altered the values allowed 
under the common use subcomponent. Variants 5–6 are 
alterations of uniqueness. Both variants changed to an 
ingredient-based approach but variant 5 was operation-
alized at the ingredient level and variant 6 was opera-
tionalized at the ingredient-route level. Variants 7–14 
are alterations of timeframe but all maintain a cross-
sectional orientation. Variants 7–9 altered the allow-
able index gap, defined as the length of time before the 
Table 1 Three component framework for constructing conceptual definitions and operational criteria for counting num-
ber of drugs
Component Description and explanation/examples
1. Scope What types of products will be considered drugs?
Each drug product used by a patient can be classified according to these five subcomponents: (a) prescription drug status, (b) 
drug type, (c) route of administration, (d) dosage form, and (e) common use. This is not an exhaustive list of subcomponents. 
The investigator can create additional subcomponents as needed for the specific study objectives, such as therapeutic cat-
egory or pregnancy category. Possible values for each of the five subcomponents are given below for illustrative purposes and 
are not intended to be exhaustive
Prescription drug status: prescription drug, over-the-counter drug
Drug type: standard drug, vitamin, herbal, dietary supplement, other complementary and alternative medicine
Route of administration: oral, inhalation, topical, transdermal, ophthalmic, subcutaneous, sublingual, rectal
Dosage form: tablet, capsule, cream, solution, suspension
Common use: regular, as needed
For each subcomponent, decisions must be made about which values will be counted as drugs, even if the decision is to 
include all possible values for a subcomponent. For example, will prescription and over-the-counter products be counted as 
drugs? Will vitamins, herbals, dietary supplements, or other various complementary and alternative medicine products be 
counted in addition to standard drugs? Will certain routes of administration be excluded? Will all dosage forms be counted? 
Will drug products commonly used on an “as needed” basis be included along with those commonly used on a regular basis?
2. Uniqueness Will an ingredient-based or product-based approach be used?
In an ingredient-based approach, drug products are dissected into their ingredients, and unique ingredients are counted. Single 
ingredient products contribute one to the count while combination products contribute at least two to the count of ingredi-
ents. When multiple drug products include the same ingredient, that ingredient is counted only once. When drug products 
are dissected into their ingredients, those ingredients can be counted based solely on ingredient (e.g. albuterol), or descrip-
tive information can be appended to an ingredient to count at a more detailed level of ingredient-route (e.g. albuterol-oral), 
ingredient-route-form (e.g. albuterol-oral-tablet), or ingredient-route-form-strength (e.g. albuterol-oral-tablet-2 mg). For the 
sake of illustration, consider a regimen including: (1) a combination inhaler containing albuterol and ipratropium, (2) albuterol 
nebulizer solution, and (3) albuterol oral tablets. The ingredient-based count at the ingredient level is 2 drugs, 1 for albuterol 
and 1 for ipratropium. The ingredient-based count at the ingredient-route level is 3 drugs, 1 for albuterol-inhalation, 1 for 
ipratropium-inhalation, and 1 for albuterol-oral
In a product-based approach, unique drug products are counted. Combination products contribute one to the count regardless 
of the number of ingredients in the product. Drug products can be counted at the ingredient(s)-route-form-strength level 
(e.g. albuterol/ipratropium-inhalation-aerosol-100 mcg/20 mcg) or at a more general level of ingredient(s)-route-form (e.g. 
albuterol/ipratropium-inhalation-aerosol), ingredient(s)-route (e.g. albuterol/ipratropium-inhalation), or ingredient(s) (e.g. 
albuterol/ipratropium). Considering the illustrative regimen described above, the product-based count at the ingredient(s)-
route-form level is 3 drugs, 1 for albuterol/ipratropium-inhalation-aerosol, 1 for albuterol-inhalation-solution, and 1 for 
albuterol-oral-tablet
3. Timeframe Will a cross-sectional or longitudinal orientation be used?
For cross-sectional analyses, what criteria will be used to determine whether a drug was in the regimen at the specified point in 
time?
Cross-sectional vs. longitudinal orientation. A cross-sectional orientation seeks to count the number of drugs in a regimen at a 
specific point in time. In contrast, the longitudinal orientation asks how many unique drugs the patient has used over some 
period of time (e.g. 1 year). Thus, the longitudinal orientation includes all drugs present in the regimen at the end of the time 
interval plus all drugs that had been used and discontinued during the interval
Timeframe criteria for cross-sectional analyses. The choice of criteria for the cross-sectional orientation is driven by the data 
source. Drug use data collected from patient interview or questionnaires will often ask the patient about what drugs they 
took yesterday or within some relatively short time frame (e.g. last 7 days). Studies using inpatient drug administration records 
would typically count unique drugs administered on a given day. Pharmacy refill databases are another common data source 
and require a more thorough examination (Fig. 1)
Other considerations Additional considerations can be implemented using variations of these 3 basic components to accomplish study specific 
objectives. Some examples using a standard specification for most drugs, but applying different criteria for selected types of 
drugs based on study specific needs are:
A study focused on asthma may apply specialized criteria for inhaled dosage forms
A study focused on pain management may apply a wider allowable index gap (defined as the length of time before the index 
date in which a drug must be filled to be counted, Fig. 1) for drug products commonly used on an “as needed” basis
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index date in which a drug must be filled to be counted 
(Fig. 1). Variant 10 incorporated post-index fills, variant 
11 incorporated the prior fill history, variant 12 incorpo-
rated hospitalizations, and variants 13–14 apply different 
allowable index gaps to different drugs. The allowable 
index gap and other elements of Fig. 1 are only applicable 
to the timeframe component and only when using phar-
macy refill databases.
Data analysis
Drug count for each count measure algorithm was 
expressed by the median and the 25th, 75th, and 95th 
percentiles. In addition, frequency distributions of the 
proportion of beneficiaries experiencing a change in 
count of 0, 1 or ≥2 drugs between the default measure 
and each variation of the default were produced. Analy-
ses were performed using SAS 9.4. The University of 
Iowa institutional review board approved the research 
and waived the requirement for informed consent (IRB 
ID # 200908724).
Results
Sixty percent of beneficiaries were more than 75  years 
old, 43 % were male, and 83 % were non-Hispanic whites. 
Thirty-four percent were dually enrolled in Medicare and 
Medicaid at the time of AMI hospitalization, and 6  % 
received the low-income subsidy. Fourteen percent were 
in the Medicare Part D “donut hole”. Eighty-two percent 
had uncomplicated hypertension, 68  % had hyperlipi-
demia, 37  % had diabetes, 30  % had heart failure, 26  % 
had COPD, 18 % had chronic kidney disease, and 7 % had 
asthma.
Using the default measure, the median count of drugs 
was 4 (Table 2). Most variations did not result in differ-
ent median or 25th percentile values, but yield differ-
ences in the higher tail of the distribution (75th and 95th 
Table 3 Fill history for a hypothetical patient obtained from a pharmacy refill database
Fill date Medication Quantity Days supply
04/19/08 Estradiol 0.025 mg/24 h transdermal patch 4 28
04/19/08 Metoprolol succinate 50 mg extended-release tablet 30 30
04/19/08 Ezetimibe/simvastatin 10/10 mg tablet 30 30
04/19/08 Nitroglycerin 0.4 mg sublingual tablet 25 9
05/20/08 Estradiol 0.025 mg/24 h transdermal patch 4 28
05/20/08 Metoprolol succinate 50 mg extended-release tablet 30 30
05/20/08 Ezetimibe/simvastatin 10/10 mg tablet 30 30
06/18/08 Estradiol 0.025 mg/24 h transdermal patch 4 28
06/18/08 Metoprolol succinate 50 mg extended-release tablet 30 30
06/18/08 Ezetimibe/simvastatin 10/10 mg tablet 30 30
07/01/08 Admission to hospital for AMI
07/03/08 Discharge from hospital
07/03/08 Lisinopril 10 mg tablet 30 30
07/19/08 Estradiol 0.025 mg/24 h transdermal patch 4 28
07/19/08 Metoprolol succinate 50 mg extended-release tablet 30 30
07/19/08 Ezetimibe/simvastatin 10/10 mg tablet 30 30
Index Date-30-60-90-120 30 60
Observed
Index GapPrior Fill History
Last Fill Prior to Index
Post-Index Period
First Fill After Index
Pre-Post Fill Gap
Fig. 1 Three key elements in using pharmacy refill databases to 
determine a cross-sectional drug count. (1) Allowable index gap: The 
first element is the allowable index gap, which is the length of time 
before the index date in which a drug must be filled to be counted. 
The investigator assigns a fixed or flexible allowable index gap. A 
fixed allowable index gap does not vary by fill (e.g. 90 days for all fills). 
A flexible allowable index gap varies between fills because it is based 
on data specific to a fill (e.g. days supply of the last fill prior to index). 
The observed index gap is the time between the last fill prior to index 
and the index date. If the observed index gap is less than the allow-
able index gap, then the drug is included in the count. (2) Post-index 
fills: The second element is whether to consider fills that occur after 
the index date. This involves calculating the observed pre-post fill 
gap, which is the time between the last fill prior to index and the first 
fill after index. If the observed pre-post fill gap is less than the fixed 
(e.g. 90 days) or flexible (2 times the days supply of the last fill prior to 
index) allowable pre-post fill gap assigned by the investigator, then 
the drug is included in the count. (3) Prior fill history: The third element 
is whether to consider fills that occurred further back in time than the 
last fill prior to index. The rationale is to estimate the drug supply the 
patient had on-hand at the time of the last prior fill. For example, if 
the patient’s last fill prior to index occurred 27 days following a prior 
fill of 30 days supply, they would be estimated to have 3 remaining 
days on hand, which can be incorporated into the allowable index 
gap for this drug
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percentiles). Variations that produced a difference in 
median included lengthening the allowable index gap to 
1.2 times the days supply (variant 7), allowing an allow-
able index gap of 90 days (variant 8), allowing an allow-
able index gap of 180 days (variant 9), and expanding the 
allowable index gap for drugs commonly used on an “as 
needed” basis (variant 13).
The impact of variations was also examined in terms 
of the proportion of patients who experienced a given 
change in drug count compared to the default meas-
ure. Drug count values remained unchanged in the vast 
majority of patients (>90 %) for the variations inclusion of 
over-the-counter products (variant 1), exclusion of drugs 
administered by a particular route (e.g. topical, variant 3), 
adjustment to the allowable index gap for hospitalization 
(variant 12), and expansion of the allowable index gap for 
a specific dosage form (e.g. metered-dose inhalers, vari-
ant 14) (Table  2). In contrast, fewer than 30  % of drug 
counts were unaffected when index gaps of 90 days (vari-
ant 8) and 180 days (variant 9) were allowed. The major-
ity (>50 %) changed by at least two drugs for variants 8 
and 9, and over 10 % changed by one drug.
Discussion
The objective of this study was to propose a three com-
ponent framework, demonstrate how operational criteria 
for number of drugs can be created using the framework, 
and then examine the impact of altering various com-
ponents. Looking across variants, the most substantial 
changes in the number of drugs were seen with altera-
tions to the timeframe component. Compared to the 
default measure, applying a fixed allowable index gap (i.e. 
look-back period) of 90  days (variant 8) increased the 
median drug count from 4 to 6, and counts changed by at 
least two drugs for 53 % of patients. Extending the look-
back period to 180 days (variant 9) increased the median 
drug count to 8, and counts changed by at least two drugs 
for 73 % of patients. The drugs counted under variants 8 
and 9 but not under the default include drugs to which 
the patient was nonadherent, drugs taken on an “as 
needed” or otherwise irregular basis, and drugs taken in 
the past but no longer in use. Jackevicius and colleagues 
used a look-back period of 120 days and found a median 
of 5 drugs for elderly patients admitted for AMI, support-
ing our results that look-back periods of ≥90  days pro-
duce higher medians than the default measure [9]. The 
changes in patients’ counts between methods highlight 
the need for future studies examining the consistency 
of results using different methods to count drugs. Other 
alterations of the timeframe component had less impact 
than extending the look-back period.
A limited number of studies have previously exam-
ined the impact of altering timeframe criteria on drug 
count. Bjerrum and colleagues compared the mean 
number of drugs used each day over one year to fills in a 
3-month window during that year [5]. The 75th percen-
tile increased, as it did when we changed the operational 
criteria for timeframe from the default specification to 
a 90-day look-back period. However, their 75th percen-
tile increased by less than one drug, from 0.3 to 1, while 
ours increased by three drugs. Fincke and colleagues 
compared the mean number of drugs used on 40  days 
over an 18-month study period to fills in a 178-day win-
dow during that study period [6]. The mean number of 
drugs increased by nearly one drug, from 2.63 to 3.54, 
but when we changed from the default specification to a 
180-day look-back period, our median increased by four 
drugs. They also compared fills in a 132-day window to 
fills in the 178-day window. Again, the increase in the 
mean was less than one drug, from 3.06 to 3.54. When 
we extended the look-back period from 90 to 180  days, 
the median drug count increased by 2. Timeframe altera-
tions may have had a greater impact in our study because 
our population of patients hospitalized for AMI was 
more severely ill with more comorbid conditions, neces-
sitating more drug use and drug changes over time than 
their populations without index events. In addition, the 
shift in 75th percentile values in our study could reflect a 
growing subgroup of patients taking a very large number 
of drugs, which skews the upper end of the drug count 
distribution. We are unable to compare the proportion 
of patients who experienced a change in drug count with 
other studies because no studies have characterized how 
many patients’ counts change or how much their counts 
change with changes in timeframe criteria.
Alterations to the scope and uniqueness components 
had little impact on the number of drugs. The large pro-
portion of counts unaltered when restricting to orally 
administered prescription drugs (variant 2) indicates 
most regimens were composed of only oral drugs. The 
large proportion unaltered when expanding to include 
over-the-counter products (variant 1) means most regi-
mens were composed of only prescription drugs or the 
majority of over-the-counter drugs used by patients were 
not counted. Few over-the-counter products appear in 
the data, as they are generally not reimbursed by Medi-
care Part D plans. The large proportion unaffected when 
changing uniqueness from a product-based to ingredi-
ent-based approach implies most regimens included only 
single ingredient products, and most did not contain the 
same ingredient administered via different routes.
The results are not intended to imply that one opera-
tional criterion is more appropriate to use than another. 
The appropriateness of a particular criterion depends 
on the study objectives and desired conceptual defini-
tion. Thus, conceptual definitions need to be specified 
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so judgment can be made on whether the chosen opera-
tional criteria are appropriate for the conceptual defini-
tion. For example, variants 8 and 9 are more likely than 
the default to count drugs that were used in the past but 
are no longer in use, making the count a summation of 
drugs taken at a point in time and drugs no longer in use. 
When a cross-sectional orientation is desired, careful 
evaluation needs to be made to determine if look-back 
periods of more than 90 days are appropriate. Assessing 
when certain operational criteria are inappropriate for a 
particular conceptual definition was outside the scope of 
this study, but a future study examining this is warranted.
Several limitations must be considered when interpret-
ing our findings. First, we used a pharmacy refill data-
base as our source of drug regimen information and did 
not examine other sources such as patient interview or 
drug administration records. These data sources would 
be more likely to contain use of over-the-counter drugs, 
drugs used on an “as needed” basis, and drugs used only 
in specific circumstances, like antibiotic prophylaxis for 
dental procedures. While we found little impact of the 
scope component of our framework when applied to 
pharmacy refill databases, this component may have a 
greater impact in other data sources where these drugs 
are more thoroughly captured. In addition, pharmacy 
refill databases do not provide information about other 
products not reimbursed by the plan, including drugs 
purchased out-of-pocket and drug samples. It is unclear 
what impact the addition of these drugs would have on 
our findings. A further limitation is that we generated 
results for a single clinical population. Other components 
of the framework may be more important in different 
clinical populations. For example, drug counts in children 
hospitalized for an asthma exacerbation would be more 
impacted by methodology variants to route of adminis-
tration, where drugs administered by inhaler or nebulizer 
are ubiquitous. Further research applying our frame-
work to drug count methodology variations in other data 
sources and clinical populations is clearly needed.
Conclusion
We contribute to the literature by proposing a frame-
work that can be used by investigators selecting the 
approach for counting number of drugs for their studies. 
This framework offers an avenue for succinctly describ-
ing the chosen approach, which is critical when brevity 
is required. For example, the investigator can refer to the 
three components without describing them at length. 
Our results highlight the need to carefully select and 
describe methodology for counting number of drugs. 
Reporting of the conceptual definition and operational 
criteria for timeframe is particularly important when the 
source of drug regimen information is a pharmacy refill 
database. For a cohort of elderly patients, extending the 
timeframe over which fills from a pharmacy refill data-
base could be counted toward the drug count on the day 
of admission for AMI changed the number of drugs by at 
least two drugs for most of the cohort. Future research 
using other sources of drug regimen information and 
additional populations are needed to fully understand 
how the methodology chosen for counting number of 
drugs influences the counts.
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